Zhenhe Technology releases an integrated IVD solution, deploying molecular diagnostic automation

Recently, the "First Zhenhe IVD Tumor Precision Diagnosis and Treatment Conference" was successfully held in Wuxi

The conference specially invited Professor Liang Zhiyong from Peking Union Medical College Hospital, Professor Bu Hong from West China Hospital of Sichuan University, Professor Liu Dongge from Beijing Hospital, and Executive Vice President Hu Jianwei of Wuxi Medical Association as the chairmen of the conference

At this conference, Zhenhe Technology released a new IVD overall solution for the first time, including the first domestic NGS companion diagnostic kit that focuses on colorectal cancer, the Genecast Genius G1 automatic sample processing system, and the Genecast INTEGRO V1.

Facing difficulties and creating an overall solution for IVD

Molecular diagnosis is the cornerstone of precision medicine

Adhering to the development concept of "clinical demand-oriented", Zhenhe Technology has actively created a complete set of complete, reliable and innovative IVD overall solutions in response to the difficult situation of NGS technology, which has truly achieved full-process automation.

Break the predicament and help NGS technology land in hospitals

Faced with the various pain points of the difficulty of NGS implementation, Zhenhe Technology has launched three major colorectal cancer NGS multi-gene companion diagnostic kits, Genecast Genius G1 automatic sample processing system and Genecast INTEGRO V1.

The kit released this time is a multi-locus companion diagnostic product based on the NGS platform, which can be used to qualitatively detect a variety of KRAS, NRAS, BRAF and PIK3CA genes in tumor samples from patients with colorectal cancer that are closely related to targeted therapy.

Specifically, in terms of detection range, the kit can detect multiple NCCN/CSCO guidelines clearly recommended colorectal cancer targeted drug-related gene loci; in terms of detection accuracy, the product has passed multi-center large samples The registered clinical research confirmed that compared with the marketed products or the gold standard method, the overall test result compliance rate exceeded 99%; in addition, the kit is more compatible and can match the high and low-throughput sequencing of MiSeq Dx and NextSeq CN500 Platform

Regarding the approval of this kit, Professor Xue Weicheng from Peking University Cancer Hospital believes that this shows that the state, government and industry authorities have issued instructions.

Professor Liu Yueping from the Fourth Hospital of Hebei Medical University also said in an interview, “Currently emerging molecular diagnostic technologies, such as NGS detection, cover more sites.

At the same time, NGS database construction is the key to obtaining high-quality nucleic acid sequencing data.

The Genecast Genius G1 fully automatic sample processing system launched by Zhenhe Technology this time adopts an integrated design.

Genecast INTEGRO V1.
0 Fully Automatic Bio-information Analysis Integrated Machine

In addition to the kit and the library building instrument, the Genecast INTEGRO V1.
0 fully automated bio-analysis integrated machine released this time is a high-performance, fully automated, and scalable bioanalysis system and data management specially built for tumor NGS laboratories.
One-stop service platform
.
It integrates data management, biometric analysis, result display, and report interpretation, and meets the clinical application requirements of tumor genetic testing for quality control management, analysis speed, and report interpretation of off-machine data to the greatest extent
.
At the same time, the patented core algorithm and secure storage technology independently developed by Zhenhe Technology can ensure accurate analysis during operation and ease data security
.

Intensive cultivation and provide more personalized solutions

Driven by the improvement of medical quality and technology, China's IVD industry has developed rapidly
.
At present, IVD has a very high clinical use rate, and its role in the field of tumor treatment is particularly obvious
.
From the perspective of market demand, the number of domestic cancer patients is huge.
With the successive launch of anti-tumor targeted drugs and the improvement of people's awareness of the IVD market, companion diagnosis will have a huge market development space in the future
.
Zhenhe Technology is also actively accelerating its deployment.
This strategic layout has not only brought technological changes to the industry and promoted development, but also created more possibilities for improving the quality of life of cancer patients, which is of great significance
.

Du Bo, Founder and CEO of Zhenhe Technology

As Mr.
Du Bo, founder and CEO of Zhenhe Technology, said at the meeting, “We hope to better empower hospitals and doctors, use more tools and methods to fight cancer, and provide patients with better treatment methods.
And quality of life
.
” Du Bo said that Zhenhe Technology’s mission is to provide the most professional and accurate diagnosis and become a trusted decision-making partner in the process of cancer diagnosis and treatment
.

From early genetic screening to molecular diagnosis, from prognostic risk assessment to dynamic recurrence monitoring to precise medication and drug resistance monitoring, Zhenhe Technology has created a comprehensive and diverse range of precise tumor diagnostic products, and continues to lead new trends in the development of the industry with technological innovation
.
With the successful conclusion of this conference, Zhenhe Technology opened a new set sail in the IVD market
.

If a worker wants to do his job well, he must first sharpen his tools
.
In the future, in addition to intensive cultivation in the original advantageous areas, Zhenhe Technology will also plan the IVD product line according to the "short-term-mid-term-long-term" phase to provide more personalized solutions for tumor diagnosis and benefit more patients
.